Navigation Links
The Breast Cancer Therapeutics Market in Australia
Date:8/5/2009

, chemotherapy continues to be used widely for now. This may be attributed to the fact that the use of targeted therapy is limited due to access and affordability issues, thereby making those complements rather than substitutes for chemotherapy. "Due to higher cost compared to cytotoxic and hormonal therapies, the use of targeted therapies in Australia is and will continue to be largely dependent on their price and availability on the Pharmaceutical Benefits Scheme (PBS)," says Gaffud.

Currently, only Herceptin (for early stage breast cancer patients) and Tykerb (for advanced/metastatic breast cancer patients) are subsidized through the PBS. Nonetheless, innovative targeted therapies are showing great promise and are being touted as the future of breast cancer treatment. Combinations of these highly specific therapies with existing cytotoxic and hormonal therapies will soon become the standard of oncology care.

Frost & Sullivan's latest research service on The Breast Cancer Therapeutics Market in Australia provides competitive structure, market analysis and future trends for the breast cancer drug therapies (cytotoxic, hormonal and targeted) in Australia.

This analysis is available through our Pharmaceutical & Biotechnology Growth Partnership Services programme. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services programme ensures that you and your Growth Team(TM) are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leade
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
2. Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
3. Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer
4. New MRI technique could mean fewer breast biopsies in high-risk women
5. Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
6. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
7. DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research
8. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
9. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
10. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... The “Global Synthetic Biology Market (2013-2018)”, analyses ... and challenges. , The global synthetic biology market ... Fisher Scientific, Inc. (U.S.), DuPont (U.S.), and Royal ... approximately ~65% of the total synthetic biology market. ... Report @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html , Thermo Fisher ...
(Date:12/13/2014)...  Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused ... Veronica G. H. Jordan , Ph.D., and David ... bringing the total number of directors to eight, seven ... LaFrance , Chairman, President, and Chief Executive Officer of ... appointments of Veronica and David to our board of ...
(Date:12/13/2014)... SAN ANTONIO , Dec. 12, 2014 /PRNewswire/ ... presentation of data at the San Antonio Breast Cancer ... epoetin alfa plus best supportive care (BSC) versus BSC ... breast cancer receiving standard chemotherapy. This non-inferiority trial did ... out a 15 percent or greater increase in the ...
(Date:12/12/2014)... Pittcon is pleased to announce ... over 2,000 technical presentations offered in symposia, oral ... program covers a wide range of applications such ... discovery, environmental, food science, fuels/energy, genomics, lab management, ... The Technical Program begins on Sunday, March 8 ...
Breaking Biology Technology:Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 2Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 3
... of person to staff customer support centers. These specialists must ... of a complicated computer system, and then be able to ... Finding these very talented people is not an easy task, ... high degree of technical aptitude. But there is more to ...
... of Fiserv, Inc. has announced the launch ... self-funded health care market. , , Fiserv Health ... administration services for self-funded medical, dental, vision and disability ... now has an integrated suite of medical management programs ...
... named to the top five in the "specialty niche" ... KLAS , a provider of healthcare information technology (HIT) ... score for all time and attendance system vendors scoring ... Performance award. , , KLAS provides the ...
Cached Biology Technology:Hope For Some U.S. Tech Workers 2Hope For Some U.S. Tech Workers 3Fiserv Launches Avidyn Health to Target Healthcare Costs 2API Receives Top 5 Recognition in "Best In KLAS" Awards 2
(Date:12/10/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) ... Market in Japan 2014-2018" report to their ... The integration of biometrics and smart ... upgradation of the driver,s license is one of ... the aforementioned projects, biometrics is being used as ...
(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2
... study to conserve and restore endangered horse mussel reefs ... University,s marine research and outreach centre in Portaferry in ... Biological Sciences, will provide scientific and technological research to ... restore it. Horse mussel reefs are important to ...
... one of the major threats to biodiversity and in ... human health. For their effective management it is important ... highest risk of being invaded. The first map ... Union was published in the Wiley-Blackwell journal Diversity ...
... Amsterdam, The Netherlands, January 22, 2009 A growing ... to delay age-related cognitive decline, including in some cases ... published in the January 2009 issue of the ... PhD, of the Center for Cellular Neurobiology; Neurodegeneration Research ...
Cached Biology News:Queen's University Belfast works to save Strangford horse mussels 2
...
Ultra-sensitive, non-radioactive detection of rat Osteopontin...
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Biology Products: